Serum Institute and Dynavax Technologies have stated in a statement that they have began dosing 39 of healthy volunteers as part of the Phase 1 of the clinical trial. Serum has been using Dynavax developed CpG 1018 in its vaccine as an adjuvant to boost the efficacy of it.